Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Impact · against what's priced in

Guardant Health shows strong fundamental momentum with a 335% surge in screening volumes and a strategic partnership with Quest Diagnostics. These drivers are fueling accelerating quarterly revenue growth, providing a positive outlook for the stock.

GH+0.70

No priced-in read yet

In context

The 335% year-over-year increase in screening volumes and a collaboration with Quest Diagnostics to reach 50 million Americans provide a clear catalyst for scaling revenue.

Read from the article alone

• revenue growth
• healthcare
• biotech
• DGX
• GH
• cancer screening
• diagnostics
• liquid biopsy

Search tags